Clinical Trial Update: Safety and Efficacy Study of Recombinant Human Lactoferrin to Treat Severe Sepsis [Phase 2]

View source ↗

Summary

This document reports the completion of a Phase 2 safety and efficacy study evaluating recombinant human lactoferrin for severe sepsis, sponsored by Agennix.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sepsis

Drugs mentioned

• Recombinant human lactoferrin (recombinant human lactoferrin)

Snippet

Sponsor: Agennix | Conditions: Severe Sepsis | Phase 2 | Status: COMPLETED